Sirios Capital Management Boosts DexCom Stake by 75%

Hedge fund increases holdings in medical device company to over 340,000 shares

Mar. 14, 2026 at 10:56am

Got story updates? Submit your updates here. ›

Sirios Capital Management L.P. increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 74.9% in the third quarter, according to a recent SEC filing. The hedge fund now owns 340,170 shares of the medical device company, making it one of DexCom's largest institutional investors.

Why it matters

DexCom is a leading manufacturer of continuous glucose monitoring (CGM) systems, which are an important tool for diabetes management. Sirios Capital's increased investment signals their confidence in DexCom's growth potential and the continued adoption of CGM technology.

The details

According to the 13F filing, Sirios Capital purchased an additional 145,682 shares of DexCom during the third quarter, bringing their total holdings to approximately 0.09% of the company. DexCom's CGM systems allow people with diabetes to continuously monitor their glucose levels, providing real-time data to help manage the condition.

  • Sirios Capital increased its DexCom stake in the third quarter of 2026.

The players

Sirios Capital Management L.P.

A hedge fund that has increased its holdings in medical device company DexCom, Inc.

DexCom, Inc.

A medical device company that develops and manufactures continuous glucose monitoring (CGM) systems for people with diabetes.

Got photos? Submit your photos here. ›

The takeaway

Sirios Capital's increased investment in DexCom reflects the growing importance of CGM technology in diabetes management and the market's confidence in DexCom's ability to capitalize on this trend.